clinical trial · NCT07266766
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
Humanis Saglık Anonim Sirketi·phase1·completed·n = 40
Type 2 Diabetes Mellitus (T2DM)Empagliflozin / Metformin HCl XR TabletsSynjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)
brief summary
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, two way crossover, Oral Bioequivalence Study of test product of Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet and Reference product of Synjardy XR tablets 25mg/1000mg in Healthy, adult, human Subjects Under fed Condition.
started
Aug 5, 2025
primary completion
Sep 24, 2025
completion
Oct 6, 2025
last updated
Dec 5, 2025
official title
An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study of Test Product of Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet and Reference Product of Synjardy XR Tablets 25mg/1000mg in Healthy, Adult, Human Subjects Under Fed Condition.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol